WallStSmart

AtriCure Inc (ATRC)vsBecton Dickinson and Company (BDX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 3847% more annual revenue ($22.48B vs $569.62M). BDX leads profitability with a 4.2% profit margin vs 1.9%. BDX appears more attractively valued with a PEG of 1.11. BDX earns a higher WallStSmart Score of 52/100 (C-).

ATRC

Hold

35

out of 100

Grade: F

Growth: 6.0Profit: 4.0Value: 4.7Quality: 8.5
Piotroski: 5/9Altman Z: 2.17

BDX

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ATRCUndervalued (+56.0%)

Margin of Safety

+56.0%

Fair Value

$74.75

Current Price

$54.54

$20.21 discount

UndervaluedFair: $74.75Overvalued
BDXUndervalued (+11.1%)

Margin of Safety

+11.1%

Fair Value

$203.14

Current Price

$177.85

$25.29 discount

UndervaluedFair: $203.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ATRC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

BDX1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

ATRC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
1.9%3/10

1.9% margin — thin

PEG RatioValuation
10.002/10

Expensive relative to growth rate

P/E RatioValuation
255.9x2/10

Premium valuation, high expectations priced in

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
31.2x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
4.2%3/10

4.2% margin — thin

EPS GrowthGrowth
-31.4%2/10

Earnings declined 31.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : ATRC

The strongest argument for ATRC centers on Debt/Equity. Revenue growth of 12.8% demonstrates continued momentum.

Bull Case : BDX

The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bear Case : ATRC

The primary concerns for ATRC are EPS Growth, Profit Margin, PEG Ratio. A P/E of 255.9x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

ATRC carries more volatility with a beta of 1.26 — expect wider price swings.

ATRC is growing revenue faster at 12.8% — sustainability is the question.

BDX generates stronger free cash flow (509M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (52/100 vs 35/100). ATRC offers better value entry with a 56.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AtriCure Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Want to dig deeper into these stocks?